These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 7745845)
1. An experimental myocardial infarction model in the rat and its properties. Hirata Y; Umemura K; Uematsu T; Nakashima M Jpn J Pharmacol; 1995 Jan; 67(1):51-7. PubMed ID: 7745845 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2. Takiguchi Y; Wada K; Nakashima M Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Umemura K; Kawai H; Ishihara H; Nakashima M Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043 [TBL] [Abstract][Full Text] [Related]
4. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig. Hirata Y; Takiguchi Y; Wada K; Matsuno H; Umemura K; Uematsu T; Nakashima M Eur J Pharmacol; 1993 Feb; 231(3):421-5. PubMed ID: 8449234 [TBL] [Abstract][Full Text] [Related]
5. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Takiguchi Y; Asai F; Wada K; Nakashima M Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079 [TBL] [Abstract][Full Text] [Related]
6. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Umemura K; Ishihara H; Nakashima M Thromb Res; 1995 Nov; 80(3):209-16. PubMed ID: 8578547 [TBL] [Abstract][Full Text] [Related]
7. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979 [TBL] [Abstract][Full Text] [Related]
8. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025 [TBL] [Abstract][Full Text] [Related]
9. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687 [TBL] [Abstract][Full Text] [Related]
10. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285 [TBL] [Abstract][Full Text] [Related]
11. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats. Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Umemura K; Wada K; Uematsu T; Nakashima M Stroke; 1993 Jul; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383 [TBL] [Abstract][Full Text] [Related]
14. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy. Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966 [TBL] [Abstract][Full Text] [Related]
15. Protective Effects of Ticagrelor on Myocardial Injury After Infarction. Vilahur G; Gutiérrez M; Casani L; Varela L; Capdevila A; Pons-Lladó G; Carreras F; Carlsson L; Hidalgo A; Badimon L Circulation; 2016 Nov; 134(22):1708-1719. PubMed ID: 27789556 [TBL] [Abstract][Full Text] [Related]
16. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects. Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144 [TBL] [Abstract][Full Text] [Related]
17. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
18. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates. Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258 [TBL] [Abstract][Full Text] [Related]
19. ADP plays a key role in thrombogenesis in rats. Maffrand JP; Bernat A; Delebassée D; Defreyn G; Cazenave JP; Gordon JL Thromb Haemost; 1988 Apr; 59(2):225-30. PubMed ID: 3133809 [TBL] [Abstract][Full Text] [Related]
20. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. White BP; Sullivan AT; Lumley P Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]